GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (FRA:J7Z) » Definitions » Net Margin %

Jazz Pharmaceuticals (FRA:J7Z) Net Margin %

: 9.30% (As of Dec. 2023)
View and export this data going back to 2007. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. Jazz Pharmaceuticals's Net Income for the three months ended in Dec. 2023 was €86 Mil. Jazz Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was €928 Mil. Therefore, Jazz Pharmaceuticals's net margin for the quarter that ended in Dec. 2023 was 9.30%.

The historical rank and industry rank for Jazz Pharmaceuticals's Net Margin % or its related term are showing as below:

FRA:J7Z' s Net Margin % Range Over the Past 10 Years
Min: -10.65   Med: 17.23   Max: 30.14
Current: 10.82


FRA:J7Z's Net Margin % is ranked better than
84.32% of 1027 companies
in the Biotechnology industry
Industry Median: -164.06 vs FRA:J7Z: 10.82

Jazz Pharmaceuticals Net Margin % Historical Data

The historical data trend for Jazz Pharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jazz Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.21 10.10 -10.65 -6.12 10.82

Jazz Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.76 7.78 10.91 15.10 9.30

Competitive Comparison

For the Biotechnology subindustry, Jazz Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jazz Pharmaceuticals Net Margin % Distribution

For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where Jazz Pharmaceuticals's Net Margin % falls into.



Jazz Pharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Jazz Pharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=380.401/3515.965
=10.82 %

Jazz Pharmaceuticals's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=86.339/927.944
=9.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jazz Pharmaceuticals  (FRA:J7Z) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Jazz Pharmaceuticals Net Margin % Related Terms

Thank you for viewing the detailed overview of Jazz Pharmaceuticals's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Jazz Pharmaceuticals (FRA:J7Z) Business Description

Traded in Other Exchanges
Address
Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals (FRA:J7Z) Headlines

No Headlines